Ependymoma Market Report and Forecast 2024-2032

Ependymoma Market Outlook

The ependymoma market size was valued at USD 149.86 million in 2023, driven by the increasing number of research and development activities for new treatments across the 7 major markets. The market size is anticipated to grow at a CAGR of 4.80% during the forecast period of 2024-2032 to achieve a value of USD 228.5 million by 2032.

Ependymoma: Introduction

Ependymoma is a type of brain tumour that starts in the brain or spinal cord. It is also widely known as a primary central nervous system (CNS) tumour. In many types of cancer, genes might be mutated, which can cause the growth and spread of cancer cells. The exact cause of ependymomas is still unknown. Ependymomas can develop anywhere in the CNS but they are often found near the ventricles in the brain and the central canal of the spinal cord. In rare cases, ependymomas can also form outside the CNS, such as in the ovaries. Ependymomas originate from ependymal cells, which are a type of glial cells that support the central nervous system CNS.

Patients with ependymoma in the brain may experience symptoms such as headaches, nausea, vomiting, and dizziness, among others. On the other hand, patients with ependymoma in the spine may experience back pain, numbness, and weakness in their arms, legs, or trunk, along with problems in sexual, urinary, or bowel functions.

Ependymoma Market Analysis

The rising prevalence of the condition and the rise in diagnosis is anticipated to bolster the ependymoma market demand in the coming years. In the United States, it is expected that around 200 children and teenagers will be diagnosed with ependymoma in 2023, which accounts for approximately 5% of all childhood brain cancers. Although ependymoma can occur at any age, it is most common in children under the age of 5. Males are more likely to be affected than females, and it is most prevalent in white and non-Hispanic people. Currently, approximately 13,294 people are living with this tumour in the United States. The relative 5-year survival rate for ependymoma is 83.9%, but it is important to note that many factors can affect prognosis.

The ependymoma market growth is influenced by the increasing number of clinical trials, both ongoing and open for enrollment, particularly at the University of California Health and UCSF, exhibiting an active interest in discovering novel drug treatments. The FDA's recent approvals of new drug treatments for patient suffering from ganglioglioma, astrocytoma, and oligodendrogliomas are also anticipated to aid the growth of the market.

Ependymoma Market Segmentations

Market Breakup by Type

• Subependymoma

• Myxopapillary Ependymoma

• Anaplastic Ependymoma

Market Breakup by Therapy Type

• Chemotherapy

• Radiation Therapy

• Targeted Therapy

Market Breakup by Treatment

• Medication

• Surgery

Market Breakup by Drugs

• Corticosteroids

• Antiseizure Agents

• Others

Market Breakup by Route of Administration

• Oral

• Injectable

Market Breakup by Distribution Channel

• Hospital Pharmacy

• Retail Pharmacy

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain 
  • United Kingdom

• Japan

Ependymoma Market Overview

The market growth is driven by the increasing efforts of the market players and researchers towards developing and providing the best clinical treatment possible in the market. The market is witnessing significant growth in the demand for personalised treatment due to the increasing awareness regarding targeted therapies.

The FDA approvals for new treatment therapies and drugs are significantly contributing to the ependymoma market share, leading to the increased demand for more treatments. The market is expected to witness significant growth due to the demand for new chemotherapy, targeted therapy, or immunotherapy drugs, which may also be available and can be a possible treatment option in the market. The growing support in the form of funding actions by the market players and the governments for research and development activities is further driving the demand for new treatments, propelling the market growth.

The United States is substantially leading the market driven by factors such as increased adoption of advanced techniques. It is likely to continue dominating the market in the coming years as well. The presence of rigid healthcare infrastructure, along with the rising awareness about the availability of limited treatments, is propelling the ependymoma market demand.

Ependymoma Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Novocure

• EMulate Therapeutics

• Sun Pharmaceutical Industries Ltd

• Zydus Cadila

• Torrent Pharmaceuticals Ltd

• Takeda Pharmaceutical Company

• Validus Pharmaceuticals LLC.

• Mylan N.V.

• Teva Pharmaceutical Industries Ltd.

• WOCKHARDT

• Fera Pharmaceuticals

• Novartis AG

• Baxter

• Lupin Pharmaceuticals, Inc.

Please note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report